Medicus Pharma (MDCXW) risk factors, 2025 10-K

Risks Relating to Our Business

1. 01We have a limited operating history, which may make it difficult to evaluation our current business and predict our future performance
2. 02We have a novel technology with uncertain market acceptance
3. 03The University of Pittsburgh may terminate our license agreement in certain circumstances
4. 04Our intellectual property is held under third-party licenses
5. 05Our technology may not be successful for its intended use
6. 06There is substantial doubt about the Company's ability to continue as a going concern and if the Company is unable to obtain additional financing from outside sources and/or eventually generate enough revenues, it may be forced to curtail or discontinue its operations
7. 07Future technology will require regulatory approval, which is costly and we may not be able to obtain it and we may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications
8. 08Changes in methods of manufacturing or formulation may result in additional costs or delay
9. 09We rely on external contract research organizations to provide clinical and nonclinical research services and agreements with these organizations of which one agreement is currently in place
10. 10If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell the Product, if approved, we may be unable to generate any product revenue
11. 11We rely on key personnel
12. 12We may not be able to successfully execute our business strategy
13. 13We will require additional financing in the future, which may not be available on favorable terms or at all
14. 14We have had negative operating cash flows since inception and expect to incur losses for the foreseeable future
15. 15We are in a highly competitive industry which is continuously evolving with technological changes
16. 16Our future success will depend on our ability to continually enhance and develop the Product
17. 17If we are unable to differentiate the Product from existing therapies for treatment of skin cancer, or if the FDA or other applicable regulatory authorities approve generic products that compete with the Product, the ability to successfully commercialize the Product would be adversely affected
18. 18A variety of risks associated with potential international business relationships could materially adversely affect our business
19. 19Collaboration arrangements we may enter into in the future may not be successful
20. 20Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations
21. 21We may acquire businesses or products, or form strategic alliances in the future, and we may not realize the benefits of such acquisitions or alliances
22. 22We do not have any customer commitments
23. 23Our business and operations would suffer in the event of computer system failures, cyberattacks, or a deficiency in our cyber security
24. 24We may fail to manage growth successfully which may adversely impact operating results
25. 25Any products we develop will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the ability to obtain regulatory approval in a timely manner, or at all
26. 26We may not be able to obtain marketing approval
27. 27We rely on the protection of intellectual property rights
28. 28Intellectual property rights do not necessarily address all potential threats to our competitive advantage
29. 29We may not be able to enforce our intellectual property rights throughout the world
30. 30Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate
31. 31Guidelines and recommendations published by various organizations can reduce the use of products that we may commercialize
32. 32Patent reform legislation in the United States
33. 33If we do not obtain protection under the Hatch-Waxman Amendments by obtaining data exclusivity, our business may be harmed
34. 34Risk of reduced or eliminated patent protection from non-compliance with regulatory requirements
35. 35We may infringe the intellectual property rights of others
36. 36We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might harm our ability to develop and market our products
37. 37We may become involved in lawsuits to protect or enforce our patents or our other intellectual property rights, which could be expensive, time consuming and unsuccessful
38. 38Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities and have a harmful effect on the success of our business
39. 39Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties
40. 40We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms
41. 41We may be subject to claims arising from consultants or contractors misappropriating intellectual property
42. 42Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed
43. 43If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
44. 44We use hazardous chemicals and biological materials in their business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly
45. 45If product liability lawsuits are brought against us then we may incur substantial liabilities and may be required to limit commercialization of the Product, if approved, and any other future products
46. 46Our employees, independent contractors, principal investigators, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading, which could significantly harm our business
47. 47We may be unable to adequately prevent disclosure of trade secrets and other proprietary information
48. 48Lawsuits relating to intellectual property infringement will be costly and time consuming
49. 49Intellectual property disputes could distract our personnel from their normal responsibilities
50. 50Our directors may serve as directors of other biotech companies and may have conflicts of interest
51. 51Our business is affected by macroeconomic conditions
52. 52We may be responsible for corruption and anti-bribery law violations
53. 53We are subject to foreign exchange risks
54. 54We are subject to taxation risks and changing rules by different tax authorities
55. 55We are subject to a number of risks and hazards, of which not all of them may be sufficiently insured for

Risks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance

1. 56Coverage and reimbursement may be limited or unavailable in certain market segments for the Product, which could make it difficult for us to sell the Product profitably
2. 57The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products
3. 58Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations

Risks Relating to Securities

1. 59We may experience fluctuations in market value
2. 60Our securities could be subject to large price and volume volatility
3. 61Due to the small size of our public float, our securities may experience extreme price volatility unrelated to our actual or expected operating performance, financial condition, or prospects, making it difficult for prospective investors to assess the rapidly changing value of our securities
4. 62We will need to raise additional financing in the future which may dilute our share capital
5. 63We have no history of dividends
6. 64Future sales of our common shares by our existing shareholders could cause the price of our securities to decline
7. 65We may issue, without shareholder approval, preferred shares that have rights and preferences potentially superior to those of our common shares
8. 66If equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our common shares, the price of our securities could decline

Risks Related to Being a Public Company

1. 67If we are unable for any reason to meet the continued listing requirements of the Nasdaq, such action or inaction could result in a delisting of our common shares and our Public Warrants, as applicable
2. 68We may be subject to securities litigation, which is expensive and could divert management attention